Navigation Links
The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
Date:12/10/2013

SAN FRANCISCO, Dec. 10, 2013 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter will be hosting its annual Emerging Therapies & Survivorship Conference for blood cancer patients on Saturday, January 25, 2014, from 8:30 a.m. to 12:30 p.m. PT at the Hyatt Regency San Francisco.  The Emerging Therapies & Survivorship Conference is a free event that brings the latest advances in blood cancer research and clinical trials to Northern California blood cancer patients, caregivers and healthcare professionals.  LLS is honored to be hosting keynote speaker Dan Shapiro, Ph.D., psychologist, professor, author and professional speaker, to give his notable talk, A Funny Thing Happened on My Way to Chemotherapy.

The Emerging Therapies & Survivorship Conference will begin with breakfast and a welcome message from LLS, and continue with the keynote speech, exhibitor sessions and concurrent breakout sessions.  During the breakout sessions, attendees will have the opportunity to speak with hematology experts about various blood cancers, including acute myeloid leukemia, myelodysplastic syndromes, non-Hodgkin lymphoma, and more.  To view the complete conference program agenda, please click here.

Sponsors for the 2014 Emerging Therapies & Survivorship Conference include Millennium, Genentech, Onyx Pharmaceuticals, Celgene, and Gilead and partners include Association of Northern California Oncologists, Marin Specialty Care, Redwood Regional Medical Group, Stanford Cancer Center, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, and Sutter Medical Center of Santa Rosa.

The Emerging Therapies & Survivorship Conference is a free educational event and will be taking place on Saturday, January 25, 2014, from 8:30 a.m. to 12:30 p.m. PT at the Hyatt Regency San Francisco, located at 5 Embarcadero Center, San Francisco, Calif., 94111.  Space is limited and registration is required.  To reserve your space, register online at bit.ly/emergingtherapies

For more information about the conference, contact Lauren Wilkerson, MPH, MSW, at 415-625-1115 or visit www.lls.org/gba.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer.  The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.  LLS funds lifesaving blood cancer research around the world and provides free information and support services for patients and their loved ones.

Major LLS fundraising campaigns include Team In Training, Light The Night Walk, School & Youth, Man & Woman of the Year and Leukemia Cup Regatta.  To reach the widest possible audience, LLS partners with national and regional level companies and brands, including Nike, Disney, Burlington and others.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada.  To learn more, visit www.LLS.org.  Patients and caregivers should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.Greater Bay Area Chapter OfficesSan Francisco

221 Main Street, Suite 1650, San Francisco, CA 94105, 415-625-1100Silicon Valley/Monterey

675 North First Street, Suite 1100, San Jose, CA 95112, 408-490-2666North Bay

2455 Bennett Valley Road, Suite B204, Santa Rosa, CA 95404 707-544-4350


'/>"/>
SOURCE Leukemia & Lymphoma Society - Greater Bay Area Chapter
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
3. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
4. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
5. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
6. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
7. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
8. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
9. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
10. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
11. The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... WAYNE, N.J. , May 3, 2017 /PRNewswire/ ... systems that contribute to quality enhancement and cost ... results from a study of contemporary practice demonstrating ... a first-line therapy for critically ill patients. The ... the Company,s newer large volume MEGA ® ...
(Date:5/2/2017)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce a ... AB that allows for the marketing and distribution ... analyses through the MarketResearch.com website. The new ... to complete product descriptions and tables of contents from ...
(Date:5/2/2017)... , May 2, 2017  CIVCO Radiotherapy, the ... solutions, announced today that Nat Geissel ... CIVCO since 2012 and has served as vice ... vice president and general manager, and most recently, ... "I am extremely proud of what CIVCO Radiotherapy ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... If you are thinking of a visit to San Francisco , fall ... the perfect time to visit. , Business Architecture Associates is pleased to offer 5 days ... as a 4-½ day package for individuals, and as 4-½ day corporate package for up ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... Shoreview, MN (PRWEB) , ... May 24, 2017 ... ... manufacturer of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had ... network now consists of a mix of domestic and rest of world (ROW) ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
Breaking Medicine News(10 mins):